Arecoline

DB04365

small molecule experimental

Deskripsi

An alkaloid obtained from the betel nut (Areca catechu), fruit of a palm tree. It is an agonist at both muscarinic and nicotinic acetylcholine receptors. It is used in the form of various salts as a ganglionic stimulant, a parasympathomimetic, and a vermifuge, especially in veterinary practice. It has been used as a euphoriant in the Pacific Islands.

Struktur Molekul 2D

Berat 155.1943
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

121 Data
Esmolol The risk or severity of adverse effects can be increased when Esmolol is combined with Arecoline.
Betaxolol The risk or severity of adverse effects can be increased when Betaxolol is combined with Arecoline.
Metoprolol The risk or severity of adverse effects can be increased when Metoprolol is combined with Arecoline.
Atenolol The risk or severity of adverse effects can be increased when Atenolol is combined with Arecoline.
Timolol The risk or severity of adverse effects can be increased when Timolol is combined with Arecoline.
Sotalol The risk or severity of adverse effects can be increased when Sotalol is combined with Arecoline.
Propranolol The risk or severity of adverse effects can be increased when Propranolol is combined with Arecoline.
Labetalol The risk or severity of adverse effects can be increased when Labetalol is combined with Arecoline.
Bisoprolol The risk or severity of adverse effects can be increased when Bisoprolol is combined with Arecoline.
Alprenolol The risk or severity of adverse effects can be increased when Alprenolol is combined with Arecoline.
Pindolol The risk or severity of adverse effects can be increased when Pindolol is combined with Arecoline.
Carvedilol The risk or severity of adverse effects can be increased when Carvedilol is combined with Arecoline.
Propafenone The risk or severity of adverse effects can be increased when Propafenone is combined with Arecoline.
Acebutolol The risk or severity of adverse effects can be increased when Acebutolol is combined with Arecoline.
Nadolol The risk or severity of adverse effects can be increased when Nadolol is combined with Arecoline.
Bevantolol The risk or severity of adverse effects can be increased when Bevantolol is combined with Arecoline.
Practolol The risk or severity of adverse effects can be increased when Practolol is combined with Arecoline.
Penbutolol The risk or severity of adverse effects can be increased when Penbutolol is combined with Arecoline.
Oxprenolol The risk or severity of adverse effects can be increased when Oxprenolol is combined with Arecoline.
Dexpropranolol The risk or severity of adverse effects can be increased when Dexpropranolol is combined with Arecoline.
Celiprolol The risk or severity of adverse effects can be increased when Celiprolol is combined with Arecoline.
Nebivolol The risk or severity of adverse effects can be increased when Nebivolol is combined with Arecoline.
Bufuralol The risk or severity of adverse effects can be increased when Bufuralol is combined with Arecoline.
Bopindolol The risk or severity of adverse effects can be increased when Bopindolol is combined with Arecoline.
Bupranolol The risk or severity of adverse effects can be increased when Bupranolol is combined with Arecoline.
Indenolol The risk or severity of adverse effects can be increased when Indenolol is combined with Arecoline.
Arotinolol The risk or severity of adverse effects can be increased when Arotinolol is combined with Arecoline.
Levobetaxolol The risk or severity of adverse effects can be increased when Levobetaxolol is combined with Arecoline.
Talinolol The risk or severity of adverse effects can be increased when Talinolol is combined with Arecoline.
Anisodamine The risk or severity of adverse effects can be increased when Anisodamine is combined with Arecoline.
Bucindolol The risk or severity of adverse effects can be increased when Bucindolol is combined with Arecoline.
Esatenolol The risk or severity of adverse effects can be increased when Esatenolol is combined with Arecoline.
Cloranolol The risk or severity of adverse effects can be increased when Cloranolol is combined with Arecoline.
Mepindolol The risk or severity of adverse effects can be increased when Mepindolol is combined with Arecoline.
Epanolol The risk or severity of adverse effects can be increased when Epanolol is combined with Arecoline.
Tertatolol The risk or severity of adverse effects can be increased when Tertatolol is combined with Arecoline.
Landiolol The risk or severity of adverse effects can be increased when Landiolol is combined with Arecoline.
Cimetropium Arecoline may decrease the anticholinergic activities of Cimetropium.
Pegvisomant The risk or severity of adverse effects can be increased when Pegvisomant is combined with Arecoline.
Mefloquine The risk or severity of adverse effects can be increased when Mefloquine is combined with Arecoline.
Tacrine The risk or severity of adverse effects can be increased when Tacrine is combined with Arecoline.
Sulpiride The risk or severity of adverse effects can be increased when Sulpiride is combined with Arecoline.
Profenamine The risk or severity of adverse effects can be increased when Profenamine is combined with Arecoline.
Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Arecoline.
Gallamine triethiodide The risk or severity of adverse effects can be increased when Gallamine triethiodide is combined with Arecoline.
Triflupromazine The risk or severity of adverse effects can be increased when Triflupromazine is combined with Arecoline.
Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Arecoline.
Cinchocaine The risk or severity of adverse effects can be increased when Cinchocaine is combined with Arecoline.
Pyridostigmine The risk or severity of adverse effects can be increased when Pyridostigmine is combined with Arecoline.
Nizatidine The risk or severity of adverse effects can be increased when Nizatidine is combined with Arecoline.
Galantamine The risk or severity of adverse effects can be increased when Galantamine is combined with Arecoline.
Isoflurophate The risk or severity of adverse effects can be increased when Isoflurophate is combined with Arecoline.
Diethylcarbamazine The risk or severity of adverse effects can be increased when Diethylcarbamazine is combined with Arecoline.
Procaine The risk or severity of adverse effects can be increased when Procaine is combined with Arecoline.
Minaprine The risk or severity of adverse effects can be increased when Minaprine is combined with Arecoline.
Terbutaline The risk or severity of adverse effects can be increased when Terbutaline is combined with Arecoline.
Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Arecoline.
Hexafluronium The risk or severity of adverse effects can be increased when Hexafluronium is combined with Arecoline.
Demecarium The risk or severity of adverse effects can be increased when Demecarium is combined with Arecoline.
Physostigmine The risk or severity of adverse effects can be increased when Physostigmine is combined with Arecoline.
Rivastigmine The risk or severity of adverse effects can be increased when Rivastigmine is combined with Arecoline.
Edrophonium The risk or severity of adverse effects can be increased when Edrophonium is combined with Arecoline.
Procainamide The risk or severity of adverse effects can be increased when Procainamide is combined with Arecoline.
Memantine The risk or severity of adverse effects can be increased when Memantine is combined with Arecoline.
Ambenonium The risk or severity of adverse effects can be increased when Ambenonium is combined with Arecoline.
Tubocurarine The risk or severity of adverse effects can be increased when Tubocurarine is combined with Arecoline.
Ketamine The risk or severity of adverse effects can be increased when Ketamine is combined with Arecoline.
Metoclopramide The risk or severity of adverse effects can be increased when Metoclopramide is combined with Arecoline.
Decamethonium The risk or severity of adverse effects can be increased when Decamethonium is combined with Arecoline.
Pancuronium The risk or severity of adverse effects can be increased when Pancuronium is combined with Arecoline.
Pipecuronium The risk or severity of adverse effects can be increased when Pipecuronium is combined with Arecoline.
Ginkgo biloba The risk or severity of adverse effects can be increased when Ginkgo biloba is combined with Arecoline.
Neostigmine The risk or severity of adverse effects can be increased when Neostigmine is combined with Arecoline.
Bambuterol The risk or severity of adverse effects can be increased when Bambuterol is combined with Arecoline.
1,10-Phenanthroline The risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Arecoline.
Thiotepa The risk or severity of adverse effects can be increased when Thiotepa is combined with Arecoline.
Huperzine A The risk or severity of adverse effects can be increased when Huperzine A is combined with Arecoline.
Phenserine The risk or severity of adverse effects can be increased when Phenserine is combined with Arecoline.
Regramostim The risk or severity of adverse effects can be increased when Regramostim is combined with Arecoline.
Aprotinin The risk or severity of adverse effects can be increased when Aprotinin is combined with Arecoline.
Betaine The risk or severity of adverse effects can be increased when Betaine is combined with Arecoline.
Capsaicin The risk or severity of adverse effects can be increased when Capsaicin is combined with Arecoline.
Coumaphos The risk or severity of adverse effects can be increased when Coumaphos is combined with Arecoline.
Dichlorvos The risk or severity of adverse effects can be increased when Dichlorvos is combined with Arecoline.
Fenthion The risk or severity of adverse effects can be increased when Fenthion is combined with Arecoline.
Metrifonate The risk or severity of adverse effects can be increased when Metrifonate is combined with Arecoline.
Acotiamide The risk or severity of adverse effects can be increased when Acotiamide is combined with Arecoline.
Methanesulfonyl Fluoride The risk or severity of adverse effects can be increased when Methanesulfonyl Fluoride is combined with Arecoline.
Paraoxon The risk or severity of adverse effects can be increased when Paraoxon is combined with Arecoline.
Tyrothricin The risk or severity of adverse effects can be increased when Tyrothricin is combined with Arecoline.
Ipidacrine The risk or severity of adverse effects can be increased when Ipidacrine is combined with Arecoline.
Distigmine The risk or severity of adverse effects can be increased when Distigmine is combined with Arecoline.
Tretamine The risk or severity of adverse effects can be increased when Tretamine is combined with Arecoline.
Posiphen The risk or severity of adverse effects can be increased when Posiphen is combined with Arecoline.
Methylphosphinic Acid The risk or severity of adverse effects can be increased when Methylphosphinic Acid is combined with Arecoline.
Capreomycin The therapeutic efficacy of Arecoline can be decreased when used in combination with Capreomycin.
Framycetin The therapeutic efficacy of Arecoline can be decreased when used in combination with Framycetin.
Amikacin The therapeutic efficacy of Arecoline can be decreased when used in combination with Amikacin.
Tobramycin The therapeutic efficacy of Arecoline can be decreased when used in combination with Tobramycin.
Gentamicin The therapeutic efficacy of Arecoline can be decreased when used in combination with Gentamicin.

Target Protein

Muscarinic acetylcholine receptor M1 CHRM1
Muscarinic acetylcholine receptor M3 CHRM3

Referensi & Sumber

Synthesis reference: K. S. Keshave Murthy, Allan W. Rey, Dan S. Matu, "Preparation of 1,2,5,6-tetra-hydro-3-carboalkoxypridines such as arecoline and salts of 1,2,5,6-tetrahydro-3-carboalkoxypridines and arecoline hydrobromide." U.S. Patent US6132286, issued October 17, 2000.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul